Pharmacist pleads 'not guilty' in meningitis case; New data shows Gilenya halts MS activity;

@FiercePharma: Top in FierceVaccines Thurs: Lawsuits claiming Merck lied about mumps vaccine efficacy headed to trial. Article | Follow @FiercePharma

@EricPFierce: Apotex, which has had plenty of cGMP issues of its own, is recalling generic Paxil made at GSK plant. Story | Follow @EricPFierce

@CarlyHFierce: Pre-chemo nod for Medivation's Xtandi sets up showdown with J&J's Zytiga. Report | Follow @CarlyHFierce

> A Boston-area pharmacist has pleaded not guilty to a charge stemming from the deadly 2012 U.S. meningitis outbreak. Report

> Compared with placebo, patients taking Novartis' ($NVS) multiple sclerosis drug Gilenya had a more than four times greater likelihood of achieving "no evidence of disease activity" across four different measures, new data says. Release

> India's National Pharmaceutical Pricing Authority is warning pharma companies that they face penalties if they fail to maintain minimum production levels of essential drugs. More

Medical Device News

@FierceMedDev: ICYMI: GE Healthcare, FBI allege Chinese engineer stole MRI trade secrets. Article | Follow @FierceMedDev

@VarunSaxena2: ACLA head makes case against FDA LDT regulation to Congress. Article | Follow @VarunSaxena2

@MichaelGFierce: #HIV-fighting intravaginal ring research nets $20M from NIH. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Med tech M&A beware: Top Senate Democrats reveal plan to crack down on inversions. Article | Follow @EmilyWFierce

> AliveCor teams with India's Apollo Hospitals to offer smartphone heart monitoring. Story

> Kimberly-Clark healthcare biz spinoff slated for Nov. 1. More

Biotech News

@FierceBiotech: This week's Chutes & Ladders: Clavis' Hellebø takes the helm at Sir Chris Evans-backed ReNeuron, and more. Report | Follow @FierceBiotech

@JohnCFierce: Still trending strong this AM- Google's stealthy Calico inks an R&D deal for new compounds aimed at neurodegeneration. More | Follow @JohnCFierce

@DamianFierce: $BIIB and $ABBV plan to market the monthly MS shot daclizumab as Zinbryta, filing in 2015. Article | Follow @DamianFierce

@EmilyMFierce: Read Berton Roueché's The Incurable Wound (1958) this week for class and was taken aback to discover how prevalent #rabies still is in U.S. | Follow @EmilyMFierce

> Oxygen Bio halts work on brain injury drug over enrollment woes. More

> Merck KGaA scraps a controversial PhIII comeback attempt for cancer vaccine. Story

And Finally... Penn Vet, part of the University of Pennsylvania's School of Veterinary Medicine, is joining up with scientists to isolate cancer chemicals that only dogs can smell. More (sub. req.)

Suggested Articles

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.

Pfizer CEO Albert Bourla clarified that collecting safety data means a submission or FDA authorization won't happen until late November.